Abstract
BackgroundSome patients with Corona Virus Disease 2019 (COVID-19) develop a severe clinical course with acute respiratory distress syndrome (ARDS) and fatal outcome. Clinical manifestations and biomarkers in early stages of disease with relevant predictive impact for outcomes remain largely unexplored. We aimed to identify parameters which are significantly different between subgroups.Design125 patients with COVID-19 were analysed. Patients with ARDS (N = 59) or non-ARDS (N = 66) were compared, as well as fatal outcome versus survival in the two groups.Key resultsARDS and non-ARDS patients did not differ with respect to comorbidities or medication on developing a fatal outcome versus survival. Body mass index was higher in patients with ARDS versus non-ARDS (p = 0.01), but not different within the groups in survivors versus non-survivors. Interleukin-6 levels on admission were higher in patients with ARDS compared to non-ARDS as well as in patients with fatal outcome versus survivors, whereas lymphocyte levels were lower in the different subgroups (all p<0.05). There was a highly significant 3.5-fold difference in fever load in non-survivors compared to survivors (p<0.0001). Extrapulmonary viral spread was detected more often in patients with fatal outcome compared to survivors (P = 0.01). Further the detection of SARS-CoV-2 in serum showed a significantly more severe course and an increased risk of death (both p<0.05).ConclusionsWe have identified early risk markers for a severe clinical course, like ARDS or fatal outcome. This data might help develop a strategy to address new therapeutic options early in patients with COVID-19 and at high risk for fatal outcome.
Highlights
A new type of Coronavirus, SARS-CoV (Severe Acute Respiratory Syndrome Corona Virus)-2, led to a worldwide pandemic outbreak of an infectious disease, called COVID-19 (Corona Virus Disease 2019)
We have identified early risk markers for a severe clinical course, like acute respiratory distress syndrome (ARDS) or fatal outcome
A decrease in kidney function and need for mechanical ventilation have been described as prognostic factors for fatal outcome in 5,700 patients hospitalized with COVID-19 in the New York City area [5]
Summary
A new type of Coronavirus, SARS-CoV (Severe Acute Respiratory Syndrome Corona Virus)-2, led to a worldwide pandemic outbreak of an infectious disease, called COVID-19 (Corona Virus Disease 2019). The clinical manifestation of this disease is very broad and variable, ranging from asymptomatic carriers to symptoms of acute infection of the upper airways and occasionally severe acute respiratory insufficiency and death [1,2,3]. Beside possible regional differences in health care, an age-related increase in mortality has consistently been observed. Mechanical ventilation and higher PEEP level requirements, were associated with increased mortality in 1,591 COVID-19 patients admitted to the ICU departments in the Lombardy Region in Italy [6]. Some patients with Corona Virus Disease 2019 (COVID-19) develop a severe clinical course with acute respiratory distress syndrome (ARDS) and fatal outcome. We aimed to identify parameters which are significantly different between subgroups
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
